Results 241 to 250 of about 232,812 (303)

Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials. [PDF]

Ther Adv Hematol
Osama M, Khan MH, Tahir A, Hussain A, Iftikhar A, Ali A, Khan S, Bilal Hassan M, Alam I, Khan Z, Afridi A, Ebad Ur Rehman M, Gul A, Thada PK.   +13 more
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy

Blood Cancer Journal
Karan L. Chohan, Lorenzo Gensini, Sherif Seif, Xiaowen Sun, Lei Feng, Melody R. Becnel, Mahmoud M. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, J. Christine Ye, Donna M. Weber, Robert Z. Orlowski, Sheeba K. Thomas   +13 more
doaj   +1 more source

Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series. [PDF]

Clin Hematol Int
Batgi H, Dilan Köseoğlu F, Çetin D, Başcı S, Namdaroğlu S, Akad Soyer N.   +5 more
europepmc   +1 more source

Safety of Lowering the Platelet Transfusion Threshold Before Central Venous Catheterisation in Patients With Haematological Diseases

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational before‐and‐after study including the first non‐tunnelled CVC insertion ...
Mathias Lazarevic Lindblad, Elin Pålsson, Vladimir Lazarevic, Leila Naddi, Ola Borgquist, Lars Nilsson, Maria Adrian, Björn P. Bark, Thomas Kander   +8 more
wiley   +1 more source

From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes. [PDF]

Ther Adv Hematol
Itez GG, Sunguroğlu A.
europepmc   +1 more source

Bone Marrow Fibrosis as a Predictor of Extramedullary Disease in Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT The correlation between bone marrow fibrosis (BMF) and extramedullary disease has yet to be fully elucidated in patients with newly diagnosed multiple myeloma. Therefore, we aimed to analyze the incidence of BMF in newly diagnosed multiple myeloma patients and evaluate the relationship between BMF and synchronous soft tissue extramedullary ...
Hilal Senkal, Ali Yilmaz Altay, Emine Goknur Isik, Simge Erdem, Metban Mastanzade, Gulcin Yegen, Mustafa Murat Ozbalak, İpek Yonal Hindilerden, Mustafa Nuri Yenerel, Sevgi Kalayoglu Besisik   +9 more
wiley   +1 more source

Multiple Myeloma Complicating Breast Cancer During Treatment: A Case Report. [PDF]

Curr Oncol
Guo L, Jin Z, Huang Y.
europepmc   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann, Sarah Flossdorf, Julius Keyl, Theo Leitner, Cyrus Khandanpour, Markus Maulhardt, Evgenii Shumilov, Matthias Stelljes, Lisa Leypoldt, Marie Harzer, Christoph Schaefers, Francis Ayuketang Ayuk, Bastian von Tresckow, Amelie Boquoi, Thomas Schroeder, Hans Christian Reinhardt, Christine Hanoun   +16 more
wiley   +1 more source

Correction: Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience. [PDF]

Front Oncol
Sretenovic A, Mitrovic M, Bukumiric Z, Vukosavljevic N, Kecman N, Jovanovic J, Fekete MD, Zaric E, Bila J.   +8 more
europepmc   +1 more source